异长春花碱加异环磷酰胺加顺铂联合化疗治疗晚期非小细胞肺癌

目的 评价异长春花碱加异环磷酰胺加顺铂（NIP）联合方案作为第一线化疗对晚期非小细胞肺癌病人的疗效及毒副作用。方法 化疗方案包括异长春花碱25mg/m^2 20min静脉输注第1d和第8d，异环磷酰胺1．2g/m^2 3h静脉输注第1－3d，美司纳400mg-800mg于0、4、8h静脉推注第2－3d，顺铂25mg/m^2 2h静脉输注第1－3d。每3周重复疗程。结果 共54例病人进行本项研究。51例可评价疗效，54例可评价毒性反应。总缓解率为53％，3例（6％）完全缓解，24例（47％）部分缓解。16例（31％）肿瘤稳定，8例（16％）肿瘤发展。中位缓解期7个月，全组中位生存期10个月。本化疗方案的剂量限制毒性为骨髓抑制，其中72％的病人发生3－4度中性粒细胞下降。结论 NIP是治疗晚期非小细胞肺癌有效的联合化疗方案，毒性反应能够耐受，值得进一步研究。

NAVELBINE

Objective　To evaluate the efficacy and toxicity of combination of navelbine, inosfamide and cisplatin (NIP) as first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLS).Methods　The chemotherapy regimen consisted of navelbine 25 mg/m2 by 20 minutes intravenous iv infusion on days 1 and 8, ifosfamide 1.2 g/m2 by 3 hours iv infusion on days 1～3, mesna 400 mg～800 mg by iv bolus at hours 0, 4 and 8 on days 1～3 and cisplatine 25 mg/m2 by 2 hours iv infusion on days 1～3. Courses were repeated every 3 weeks. Results　Fifty-four patients entered the study. Fifty-one patients were evaluable for response and 54 were assessable for toxicity. The over-all response rate was 53 % with 3 (6 %) CR and 24 (47 %) PR. The disease was stable in 16 patients (31 %) and was progressive in 8 patients (16 %). The median duration of response was 7 months and the median over-all survival time was 10 months. The dose-limiting toxicity ssociated with this regimen was myelo-suppression with grade 3～4 neutrocytopenia in 72 % of patients. Conclusion　The NIP combination chemotherapy is an active regimen for advanced NSCLC with tolerable toxicity and deserves further evaluation.